All In Biotech

Drug Trial Radar · NCT03162536

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Jun 26, 2017

Primary completion

Sep 17, 2027

Study completion Sep 17, 2027

Sponsor

Sponsor type
Industry
First posted
May 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

Conditions

  • Lymphoma, B-Cell
  • Small Lymphocytic Lymphoma
  • Chronic Lymphocytic Leukemia
  • Waldenstrom Macroglobulinemia
  • Mantle Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Richter's Transformation
  • Follicular Lymphoma
  • Marginal Zone Lymphoma

Interventions

  • NemtabrutinibDrug

    Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants Experiencing Dose Limiting Toxicity (DLT)Time frame: Cycle 1 (up to 28 days)
  2. Phase 1: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 86 months
  3. Phase 1: Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 86 months
  4. Phase 2: Expansion Cohorts A, B & C: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by the InvestigatorTime frame: Up to approximately 64 months
  5. Phase 2: Expansion Cohorts A, B, C: ORR per Lugano Classification as Assessed by the InvestigatorTime frame: Up to approximately 64 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital ( Site 0140)

    Scottsdale, Arizona

  • UCLA Hematology & Oncology ( Site 0017)

    Los Angeles, California

  • Colorado Blood Cancer Institute ( Site 0225)

    Denver, Colorado

  • University of Michigan ( Site 0018)

    Ann Arbor, Michigan

  • Mayo Clinic - Rochester ( Site 0138)

    Rochester, Minnesota

  • Duke Cancer Center ( Site 0067)

    Durham, North Carolina

  • The Ohio State University Wexner Medical Center ( Site 0056)

    Columbus, Ohio

  • Tennessee Oncology, PLLC ( Site 0020)

    Nashville, Tennessee

  • UT Southwestern Medical Center ( Site 0116)

    Dallas, Texas

  • University of Utah, Huntsman Cancer Institute ( Site 0122)

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.